IPSC.mesodermal_primed: Studies — page 13
How association tiers are defined — cell–trait and gene–trait
SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.
Cell–trait tiers
- Cell–trait links
- Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
- Required for Specific or Relevant
- The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
- Specific (Tier 1)
- Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
- Relevant (Tier 2)
- Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
- Interpretation and report values
- CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
- Meta traits and individual traits
- Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.
Gene–trait priorities (variant–tCRE–gene evidence)
- Variant–tCRE–gene links
- Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
- Required genetic support
- The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
- Required cellular support
- The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
- High priority
- Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
- Medium priority
- Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
- Same-record evidence and aggregation
- Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
- Limits of interpretation
- A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.
State · 1,329 full-atlas cells · all tissues.
Marker genes and cell annotation · Open this population in Cell Browser →
ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.
Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.
| # | Trait / study | Individual trait ID | Mean IC score |
|---|---|---|---|
| 12001 | RNF5 levels | GCST90470488 | 8.39e-06 |
| 12002 | DCTN1/TRIAP1 ratio | GCST90314434 | 8.38e-06 |
| 12003 | DAG1/PDGFB ratio | GCST90314379 | 8.35e-06 |
| 12004 | Crohn's disease | GCST90446793 | 8.31e-06 |
| 12005 | CD84/VASH1 ratio | GCST90313920 | 8.26e-06 |
| 12006 | PTPRM/SELE ratio | GCST90315753 | 8.18e-06 |
| 12007 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 8.15e-06 |
| 12008 | GZMA levels | GCST90469423 | 8.13e-06 |
| 12009 | FUT8/TNFSF12 ratio | GCST90314894 | 8.04e-06 |
| 12010 | IL1R1/IL1RN ratio | GCST90315158 | 7.98e-06 |
| 12011 | Total lipids in large HDL (UKB data field 23559) | GCST90269656 | 7.93e-06 |
| 12012 | TIMP1 levels | GCST90470869 | 7.89e-06 |
| 12013 | Ulcerative colitis, NAS | FING00001390 | 7.86e-06 |
| 12014 | BPIFA2 levels | GCST90468461 | 7.75e-06 |
| 12015 | ANKRD54 levels | GCST90468311 | 7.69e-06 |
| 12016 | FCRLB levels | GCST90469210 | 7.65e-06 |
| 12017 | SELE levels | GCST90470566 | 7.64e-06 |
| 12018 | CD101 levels | GCST90468596 | 7.58e-06 |
| 12019 | CASP3/PDGFB ratio | GCST90313638 | 7.52e-06 |
| 12020 | Liver iron content | GCST90016674 | 7.50e-06 |
| 12021 | DKK1/SDC4 ratio | GCST90314479 | 7.48e-06 |
| 12022 | Total protein levels | GCST90025995 | 7.43e-06 |
| 12023 | Other (seronegative) rheumatoid arthritis, wide | FING00000917 | 7.25e-06 |
| 12024 | DTYMK levels | GCST90469049 | 7.23e-06 |
| 12025 | DPP6 levels | GCST90469034 | 7.21e-06 |
| 12026 | GPC5 levels | GCST90469387 | 7.18e-06 |
| 12027 | PPM1B levels | GCST90470296 | 7.15e-06 |
| 12028 | CLEC4D/CLEC6A ratio | GCST90314109 | 7.15e-06 |
| 12029 | Polyarthropathies | FING00001180 | 7.13e-06 |
| 12030 | SIGLEC6 levels | GCST90470634 | 7.03e-06 |
| 12031 | White blood cell count | GCST90025985 | 7.02e-06 |
| 12032 | SIGLEC1 levels | GCST90470632 | 7.00e-06 |
| 12033 | ITGB1BP2/USP8 ratio | GCST90315223 | 6.96e-06 |
| 12034 | LPCAT2 levels | GCST90469787 | 6.93e-06 |
| 12035 | ASAH1 levels | GCST90468373 | 6.89e-06 |
| 12036 | Neutrophil percentage of white cells | GCST004633 | 6.89e-06 |
| 12037 | ALCAM/CNTN1 ratio | GCST90313235 | 6.84e-06 |
| 12038 | TNFRSF14/TNFRSF1A ratio | GCST90315935 | 6.84e-06 |
| 12039 | DCXR/KYNU ratio | GCST90314438 | 6.82e-06 |
| 12040 | ACY3 levels | GCST90468213 | 6.72e-06 |
| 12041 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 6.61e-06 |
| 12042 | Rheumatoid arthritis (PheCode 714.1) | GCST90476230 | 6.58e-06 |
| 12043 | CIAPIN1/VEGFC ratio | GCST90314071 | 6.57e-06 |
| 12044 | THPO levels | GCST90470857 | 6.52e-06 |
| 12045 | TNF levels | GCST90470924 | 6.48e-06 |
| 12046 | EPHA1 levels | GCST90469129 | 6.44e-06 |
| 12047 | Lymphocyte percentage of white cells | GCST90002389 | 6.38e-06 |
| 12048 | ARSA/CD164 ratio | GCST90313351 | 6.36e-06 |
| 12049 | MYLPF levels | GCST90469980 | 6.32e-06 |
| 12050 | SCARA5 levels | GCST90470533 | 6.27e-06 |
| 12051 | Phospholipids in large HDL (UKB data field 23560) | GCST90269657 | 6.25e-06 |
| 12052 | HDL cholesterol | GCST000755 | 6.24e-06 |
| 12053 | FKBP4/SIRT2 ratio | GCST90314841 | 6.23e-06 |
| 12054 | MEP1A levels | GCST90469887 | 6.22e-06 |
| 12055 | PTPRN2 levels | GCST90470385 | 6.16e-06 |
| 12056 | LPO levels | GCST90469789 | 6.08e-06 |
| 12057 | GBP1 levels | GCST90469311 | 6.08e-06 |
| 12058 | ITGB1/ITGB2 ratio | GCST90315225 | 6.04e-06 |
| 12059 | FKBPL levels | GCST90469246 | 6.04e-06 |
| 12060 | BGLAP levels | GCST90468440 | 6.00e-06 |
| 12061 | Phospholipids in very large HDL (UKB data field 23553) | GCST90269650 | 5.99e-06 |
| 12062 | Mucosal proctocolitis | FING00000841 | 5.94e-06 |
| 12063 | CRELD2/HYOU1 ratio | GCST90314255 | 5.86e-06 |
| 12064 | BIRC2/CD40LG ratio | GCST90313517 | 5.83e-06 |
| 12065 | DPP6/NELL2 ratio | GCST90314541 | 5.73e-06 |
| 12066 | Arachidoylcarnitine (C20) levels | GCST90200135 | 5.72e-06 |
| 12067 | PEAR1/PECAM1 ratio | GCST90315641 | 5.71e-06 |
| 12068 | PEAR1/SNAP23 ratio | GCST90315643 | 5.69e-06 |
| 12069 | CCL17/GRK5 ratio | GCST90313687 | 5.67e-06 |
| 12070 | CXCL10 levels | GCST90468923 | 5.61e-06 |
| 12071 | FHIT/PRTFDC1 ratio | GCST90314823 | 5.60e-06 |
| 12072 | AHNAK levels | GCST90468261 | 5.48e-06 |
| 12073 | Spondylopathies (FG) | FING00001326 | 5.47e-06 |
| 12074 | RETN levels | GCST90470457 | 5.44e-06 |
| 12075 | CCN4 levels | GCST90468590 | 5.42e-06 |
| 12076 | TGFB1 levels | GCST90470843 | 5.42e-06 |
| 12077 | FCRL5/TNFRSF13B ratio | GCST90314805 | 5.38e-06 |
| 12078 | PRSS53 levels | GCST90470344 | 5.28e-06 |
| 12079 | Basophil count | GCST90025997 | 5.23e-06 |
| 12080 | Cholesterol to total lipids ratio in very large HDL | GCST90093005 | 5.19e-06 |
| 12081 | Concentration of large HDL particles | GCST90497828 | 5.11e-06 |
| 12082 | Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632) | GCST90269729 | 4.97e-06 |
| 12083 | ARSA/GUSB ratio | GCST90313355 | 4.96e-06 |
| 12084 | FOXO1/SNAP23 ratio | GCST90314875 | 4.85e-06 |
| 12085 | SFRP2 levels | GCST90242727 | 4.74e-06 |
| 12086 | CLEC4D/MANSC1 ratio | GCST90314112 | 4.66e-06 |
| 12087 | CRELD2/NUCB2 ratio | GCST90314256 | 4.62e-06 |
| 12088 | Free thyroxine levels within normal range in pregnancy | GCST90435196 | 4.59e-06 |
| 12089 | RSPO1 levels | GCST90470503 | 4.59e-06 |
| 12090 | Lymphocyte percentage | Blood count | UKBB00000412 | 4.58e-06 |
| 12091 | ANGPT1/MPIG6B ratio | GCST90313265 | 4.57e-06 |
| 12092 | APOBR levels | GCST90468334 | 4.54e-06 |
| 12093 | MET levels | GCST90469895 | 4.41e-06 |
| 12094 | FKBP4/FKBP5 ratio | GCST90314838 | 4.39e-06 |
| 12095 | Severity of induration at injection site at the injection site after COVID-19 booster vaccination | GCST90454409 | 4.27e-06 |
| 12096 | Phospholipids to total lipids in very large HDL percentage (UKB data field 23629) | GCST90269726 | 4.21e-06 |
| 12097 | PIGR levels | GCST90470232 | 4.20e-06 |
| 12098 | FKBP4/WWP2 ratio | GCST90314842 | 4.19e-06 |
| 12099 | FUOM levels | GCST90469276 | 4.19e-06 |
| 12100 | HBEGF/SDC4 ratio | GCST90315037 | 4.15e-06 |
| 12101 | CRTAM/TNFRSF9 ratio | GCST90314280 | 4.12e-06 |
| 12102 | IL10 levels | GCST90469546 | 4.10e-06 |
| 12103 | PDAP1 levels | GCST90470179 | 4.03e-06 |
| 12104 | MAP4K5/STAMBP ratio | GCST90315382 | 4.02e-06 |
| 12105 | CD74/TIMD4 ratio | GCST90313896 | 3.95e-06 |
| 12106 | LTBP3 levels | GCST90469815 | 3.95e-06 |
| 12107 | CCL17/THPO ratio | GCST90313689 | 3.77e-06 |
| 12108 | CD58/SIRPB1 ratio | GCST90313855 | 3.73e-06 |
| 12109 | DLK1/PIK3IP1 ratio | GCST90314492 | 3.73e-06 |
| 12110 | YARS1 levels | GCST90471087 | 3.72e-06 |
| 12111 | BLMH/SERPINE1 ratio | GCST90313520 | 3.71e-06 |
| 12112 | PRSS27 levels | GCST90470342 | 3.66e-06 |
| 12113 | DIABLO/VSIR ratio | GCST90314470 | 3.66e-06 |
| 12114 | DNER levels | GCST90469019 | 3.61e-06 |
| 12115 | BAMBI levels | GCST90468420 | 3.57e-06 |
| 12116 | CRYZL1 levels | GCST90468878 | 3.53e-06 |
| 12117 | Atopic dermatitis | GCST90018564 | 3.42e-06 |
| 12118 | WFIKKN2 levels | GCST90471077 | 3.35e-06 |
| 12119 | NPHS1 levels | GCST90470070 | 3.34e-06 |
| 12120 | COX5B levels | GCST90468834 | 3.34e-06 |
| 12121 | GZMA/IL12A_IL12B ratio | GCST90315009 | 3.32e-06 |
| 12122 | DNAJB14 levels | GCST90469011 | 3.27e-06 |
| 12123 | FCRL5/MZB1 ratio | GCST90314804 | 3.27e-06 |
| 12124 | CIRBP levels | GCST90468756 | 3.26e-06 |
| 12125 | STIP1 levels | GCST90470764 | 3.24e-06 |
| 12126 | CHAC2 levels | GCST90468736 | 3.22e-06 |
| 12127 | Operative procedures - Unspecified diagnostic endoscopic examination of bladder | Summary Operations | UKBB00000590 | 3.17e-06 |
| 12128 | STIP1/TMSB10 ratio | GCST90315890 | 3.14e-06 |
| 12129 | PPP2R2A levels | GCST90618122 | 3.11e-06 |
| 12130 | PRR4 levels | GCST90470338 | 3.09e-06 |
| 12131 | RGMB/TNFRSF21 ratio | GCST90315772 | 3.05e-06 |
| 12132 | Malignant melanoma, excluding all cancers (controls excluding all cancers) | FING00000750 | 3.05e-06 |
| 12133 | FCRL6/KLRD1 ratio | GCST90314807 | 3.03e-06 |
| 12134 | Glomerular filtration rate (creatinine) | GCST003372 | 2.99e-06 |
| 12135 | ASRGL1 levels | GCST90468379 | 2.94e-06 |
| 12136 | FGR/LBR ratio | GCST90314814 | 2.93e-06 |
| 12137 | IFNGR1/IL10RB ratio | GCST90315127 | 2.93e-06 |
| 12138 | NID1/SORT1 ratio | GCST90315542 | 2.92e-06 |
| 12139 | OLR1/OSM ratio | GCST90315583 | 2.85e-06 |
| 12140 | CNPY4/MESD ratio | GCST90314152 | 2.81e-06 |
| 12141 | COLEC12/TNFRSF1A ratio | GCST90314187 | 2.81e-06 |
| 12142 | MAN1A2 levels | GCST90469843 | 2.80e-06 |
| 12143 | PIK3IP1/TNFRSF1B ratio | GCST90315654 | 2.74e-06 |
| 12144 | KLRK1 levels | GCST90469713 | 2.57e-06 |
| 12145 | PLXNB3/SNAP23 ratio | GCST90315693 | 2.56e-06 |
| 12146 | CRADD levels | GCST90468854 | 2.43e-06 |
| 12147 | ARSA levels | GCST90468368 | 2.40e-06 |
| 12148 | TACC3 levels | GCST90470797 | 2.40e-06 |
| 12149 | PIBF1 levels | GCST90470231 | 2.37e-06 |
| 12150 | STAT5B levels | GCST90470759 | 2.35e-06 |
| 12151 | Crohn's disease | GCST90475318 | 2.35e-06 |
| 12152 | FGFBP3 levels | GCST90469232 | 2.35e-06 |
| 12153 | FUT8 levels | GCST90469281 | 2.30e-06 |
| 12154 | SLAMF1 levels | GCST90274835 | 2.29e-06 |
| 12155 | NUB1/SRPK2 ratio | GCST90315573 | 2.28e-06 |
| 12156 | CX3CL1 levels | GCST90241204 | 2.22e-06 |
| 12157 | F9/FETUB ratio | GCST90314746 | 2.13e-06 |
| 12158 | S100A11/S100A12 ratio | GCST90315798 | 2.13e-06 |
| 12159 | Cream liking | GCST90094746 | 2.07e-06 |
| 12160 | SCG3 levels | GCST90470539 | 2.05e-06 |
| 12161 | CCN2 levels | GCST90468588 | 2.05e-06 |
| 12162 | BTN2A1/SIGLEC1 ratio | GCST90313548 | 2.00e-06 |
| 12163 | DIABLO/DOK2 ratio | GCST90314464 | 1.98e-06 |
| 12164 | FCRL2 levels | GCST90469206 | 1.96e-06 |
| 12165 | Neutrophill percentage | Blood count | UKBB00000498 | 1.95e-06 |
| 12166 | Tonsillectomy and adenotomy | FING00001367 | 1.95e-06 |
| 12167 | Mean platelet (thrombocyte) volume | Blood count | UKBB00000450 | 1.92e-06 |
| 12168 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 1.92e-06 |
| 12169 | Total lipids in very large HDL (UKB data field 23552) | GCST90269649 | 1.89e-06 |
| 12170 | Glaucoma | FING00000577 | 1.87e-06 |
| 12171 | CD74/NPDC1 ratio | GCST90313895 | 1.84e-06 |
| 12172 | APP/NID1 ratio | GCST90313326 | 1.82e-06 |
| 12173 | HNRNPUL1 levels | GCST90469470 | 1.80e-06 |
| 12174 | GALNT2 levels | GCST90469296 | 1.76e-06 |
| 12175 | GFRA1 levels | GCST90469328 | 1.75e-06 |
| 12176 | CD5L levels | GCST90468640 | 1.72e-06 |
| 12177 | DNAJB1 levels | GCST90469012 | 1.69e-06 |
| 12178 | Mean platelet volume during first trimester of pregnancy | GCST90302229 | 1.67e-06 |
| 12179 | TG levels | GCST90470851 | 1.62e-06 |
| 12180 | C1QL2 levels | GCST90468487 | 1.58e-06 |
| 12181 | DNPH1/PDGFB ratio | GCST90314527 | 1.57e-06 |
| 12182 | ADGRE1 levels | GCST90468236 | 1.56e-06 |
| 12183 | SF3B4/SIRT2 ratio | GCST90315838 | 1.51e-06 |
| 12184 | Neutrophill percentage (UKB data field 30200) | GCST90468093 | 1.49e-06 |
| 12185 | DTI autoptx L3 fmi tract | GCST90385204 | 1.48e-06 |
| 12186 | PLXNA4/SRPK2 ratio | GCST90315688 | 1.47e-06 |
| 12187 | PAMR1 levels | GCST90470155 | 1.46e-06 |
| 12188 | Aspartate aminotransferase levels | GCST90018724 | 1.45e-06 |
| 12189 | CLEC1B/PLXNA4 ratio | GCST90314100 | 1.42e-06 |
| 12190 | Average diameter for HDL particles | GCST90092828 | 1.41e-06 |
| 12191 | TMSB10/TREML2 ratio | GCST90315923 | 1.34e-06 |
| 12192 | Taking other prescription medications | Medication | UKBB00000813 | 1.33e-06 |
| 12193 | RBFOX3 levels | GCST90470432 | 1.33e-06 |
| 12194 | IL12B levels | GCST90469549 | 1.29e-06 |
| 12195 | EPHB6/VWC2 ratio | GCST90314683 | 1.29e-06 |
| 12196 | Neutrophil percentage of white cells | GCST90002399 | 1.27e-06 |
| 12197 | HSPG2/PTGDS ratio | GCST90315092 | 1.24e-06 |
| 12198 | POLR2F levels | GCST90470283 | 1.24e-06 |
| 12199 | DARS1/MAP4K5 ratio | GCST90314404 | 1.23e-06 |
| 12200 | TNFRSF13B levels | GCST90470905 | 1.22e-06 |
| 12201 | PLXNA4/SPRY2 ratio | GCST90315687 | 1.21e-06 |
| 12202 | Sphingomyelin_41:0_[M+H]1+ levels | GCST90060386 | 1.20e-06 |
| 12203 | Principal component-derived dietary pattern 33 | GCST90133038 | 1.19e-06 |
| 12204 | CD40LG/TRAF2 ratio | GCST90313828 | 1.18e-06 |
| 12205 | TP53BP1 levels | GCST90470936 | 1.17e-06 |
| 12206 | NECTIN2/VSIR ratio | GCST90315533 | 1.16e-06 |
| 12207 | Left hippocampal volume (tail) | GCST90267951 | 1.14e-06 |
| 12208 | AMIGO2 levels | GCST90468292 | 1.08e-06 |
| 12209 | EPS8L2 levels | GCST90469138 | 1.06e-06 |
| 12210 | CD300E/EFNA4 ratio | GCST90313797 | 1.05e-06 |
| 12211 | SELP levels | GCST90470569 | 1.02e-06 |
| 12212 | Suppurative and unspecified otitis media | FING00001346 | 1.00e-06 |
| 12213 | SDC4/SEMA4D ratio | GCST90315818 | 9.92e-07 |
| 12214 | ALCAM/ENPP2 ratio | GCST90313236 | 9.75e-07 |
| 12215 | LGALS9/SIGLEC1 ratio | GCST90315323 | 9.70e-07 |
| 12216 | ALB levels | GCST90025992 | 9.33e-07 |
| 12217 | DLL1/NOTCH1 ratio | GCST90314498 | 8.79e-07 |
| 12218 | FOXO1/NUB1 ratio | GCST90314874 | 8.73e-07 |
| 12219 | Enteropathic arthropathies | FING00000508 | 8.57e-07 |
| 12220 | SERPINB8 levels | GCST90470592 | 8.46e-07 |
| 12221 | CD55/PTGDS ratio | GCST90313847 | 8.35e-07 |
| 12222 | APRT/EREG ratio | GCST90313335 | 8.12e-07 |
| 12223 | NID1/TIMP3 ratio | GCST90315543 | 7.94e-07 |
| 12224 | CCL22/TIMP3 ratio | GCST90313693 | 7.82e-07 |
| 12225 | ALB levels | GCST90497108 | 7.66e-07 |
| 12226 | QPCT/RNASET2 ratio | GCST90315758 | 7.54e-07 |
| 12227 | Spicy food liking | GCST90094846 | 7.49e-07 |
| 12228 | DKK1/LGALS8 ratio | GCST90314472 | 7.41e-07 |
| 12229 | MICB_MICA/TEK ratio | GCST90315446 | 7.09e-07 |
| 12230 | HDL cholesterol | GCST002223 | 7.08e-07 |
| 12231 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 7.03e-07 |
| 12232 | INPP1/NT5C3A ratio | GCST90315177 | 7.02e-07 |
| 12233 | Platelet distribution width (UKB data field 30110) | GCST90468097 | 6.78e-07 |
| 12234 | MZB1/TNFRSF13B ratio | GCST90315509 | 6.66e-07 |
| 12235 | CES2 levels | GCST90468719 | 6.51e-07 |
| 12236 | CD8A levels | GCST90468655 | 6.42e-07 |
| 12237 | CCL11/CCL13 ratio | GCST90313671 | 6.38e-07 |
| 12238 | CD302 levels | GCST90468624 | 6.26e-07 |
| 12239 | ACVRL1 levels | GCST90468211 | 6.17e-07 |
| 12240 | OSM levels | GCST90470133 | 5.88e-07 |
| 12241 | HSPB1/QDPR ratio | GCST90315089 | 5.84e-07 |
| 12242 | LGALS4 levels | GCST90469762 | 5.82e-07 |
| 12243 | LY9 levels | GCST90469824 | 5.78e-07 |
| 12244 | Cholesterol in very large HDL (UKB data field 23554) | GCST90269651 | 5.69e-07 |
| 12245 | LAT2/MANF ratio | GCST90315277 | 5.44e-07 |
| 12246 | CD72 levels | GCST90468646 | 5.10e-07 |
| 12247 | CDH2/SSC4D ratio | GCST90313951 | 5.07e-07 |
| 12248 | Concentration of very large HDL particles (UKB data field 23551) | GCST90269648 | 4.76e-07 |
| 12249 | TNFRSF10B levels | GCST90012021 | 4.69e-07 |
| 12250 | Free cholesterol to total lipids ratio in very large HDL | GCST90093009 | 4.57e-07 |
| 12251 | HSPB1/PLIN3 ratio | GCST90315088 | 4.52e-07 |
| 12252 | ALB levels | UKBB00000019 | 4.49e-07 |
| 12253 | FABP1 levels | GCST90469173 | 4.45e-07 |
| 12254 | ALB levels | GCST90475103 | 4.42e-07 |
| 12255 | DLL1/TGFBR2 ratio | GCST90314499 | 4.42e-07 |
| 12256 | SERPINE1 levels | GCST90470596 | 4.11e-07 |
| 12257 | ALB levels | GCST90475100 | 4.00e-07 |
| 12258 | DAG1/DBNL ratio | GCST90314372 | 3.96e-07 |
| 12259 | Diseases of white blood cells (PheCode 288) | GCST90475812 | 3.95e-07 |
| 12260 | NADK/PXN ratio | GCST90315512 | 3.70e-07 |
| 12261 | SPINT2 levels | GCST90470728 | 3.68e-07 |
| 12262 | Thyroid cancer (PheCode 193) | GCST90475600 | 3.67e-07 |
| 12263 | TRAF2/WWP2 ratio | GCST90315943 | 3.63e-07 |
| 12264 | PDGFA/PRSS27 ratio | GCST90315616 | 3.53e-07 |
| 12265 | COLEC12/NBL1 ratio | GCST90314183 | 3.43e-07 |
| 12266 | SRPK2/VASH1 ratio | GCST90315886 | 2.63e-07 |
| 12267 | CETN2/TDRKH ratio | GCST90314031 | 2.55e-07 |
| 12268 | NME3 levels | GCST90470055 | 2.54e-07 |
| 12269 | Chalazion | FING00000267 | 2.48e-07 |
| 12270 | GFRA2/IL12A_IL12B ratio | GCST90314925 | 2.44e-07 |
| 12271 | CD99/KITLG ratio | GCST90313924 | 2.35e-07 |
| 12272 | FYB1 levels | GCST90469284 | 2.27e-07 |
| 12273 | Total protein levels | GCST90468105 | 2.24e-07 |
| 12274 | SDC4/WWP2 ratio | GCST90315821 | 2.23e-07 |
| 12275 | GZMA/TNFRSF4 ratio | GCST90315013 | 2.16e-07 |
| 12276 | SIRT2 levels | GCST90470642 | 1.93e-07 |
| 12277 | DLL1/NECTIN4 ratio | GCST90314497 | 1.87e-07 |
| 12278 | CLEC1B/GP1BA ratio | GCST90314091 | 1.86e-07 |
| 12279 | L3HYPDH levels | GCST90469724 | 1.86e-07 |
| 12280 | TOP2B levels | GCST90470934 | 1.85e-07 |
| 12281 | NPDC1 levels | GCST90470069 | 1.82e-07 |
| 12282 | CCL4 levels | GCST90468583 | 1.56e-07 |
| 12283 | SRP14 levels | GCST90470742 | 1.49e-07 |
| 12284 | APLP1 levels | GCST90468330 | 1.34e-07 |
| 12285 | CSF3 levels | GCST90468886 | 1.33e-07 |
| 12286 | PDGFA levels | GCST90470188 | 1.26e-07 |
| 12287 | ITGA11 levels | GCST90469633 | 1.17e-07 |
| 12288 | Total protein levels | UKBB00000826 | 1.17e-07 |
| 12289 | CLEC4D levels | GCST90468773 | 1.15e-07 |
| 12290 | Ulcerative proctitis | FING00001393 | 8.64e-08 |
| 12291 | ADA levels | GCST90468231 | 8.59e-08 |
| 12292 | LAYN/TNFRSF4 ratio | GCST90315291 | 7.30e-08 |
| 12293 | ERBB2 levels | GCST90469139 | 6.31e-08 |
| 12294 | SCARA5/SCARF2 ratio | GCST90315808 | 5.09e-08 |
| 12295 | TREML1 levels | GCST90470961 | 4.98e-08 |
| 12296 | PRL levels | GCST90470332 | 4.94e-08 |
| 12297 | IL12A or IL12B levels | GCST90469548 | 4.55e-08 |
| 12298 | PTP4A3 levels | GCST90470375 | 4.23e-08 |
| 12299 | PLXDC1 levels | GCST90470263 | 3.53e-08 |
| 12300 | CCL5/RARRES2 ratio | GCST90313704 | 2.32e-08 |
| 12301 | S100A13 levels | GCST90470514 | 2.28e-08 |
| 12302 | PIK3IP1/TNFRSF1A ratio | GCST90315653 | 2.16e-08 |
| 12303 | Cyst of kidney, acquired (PheCode 586.2) | GCST90476133 | 1.12e-08 |
| 12304 | CPXM1 levels | GCST90468849 | 1.09e-08 |
| 12305 | Ankylosing spondylitis | FING00000089 | 1.09e-08 |
| 12306 | ITGB1/REG1A ratio | GCST90315228 | 3.79e-09 |
| 12307 | DTX3 levels | GCST90469048 | 2.50e-09 |
| 12308 | CDHR2/SSC4D ratio | GCST90313965 | 2.49e-09 |
| 12309 | PLXNB2 levels | GCST90242299 | 2.47e-09 |
| 12310 | SELPLG levels | GCST90470568 | 2.28e-09 |
| 12311 | QPCT levels | GCST90470401 | 1.99e-09 |
| 12312 | TNFSF13 levels | GCST90470921 | 7.73e-10 |
| 12313 | IL18 levels | GCST90469567 | 3.35e-10 |